http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Apr 2026 01:47:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Press+Releases/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html <p align="left"><strong>EXECUTIVE SUMMARY</strong></p> <ul><li style="margin-top:3pt; margin-bottom:0in;">final European scientific advice received for pivotal Phase III vitiligo study</li><li style="margin-top:0in; margin-bottom:0in;">EMA emphasised its “totality of evidence” approach</li><li style="margin-top:0in; margin-bottom:0in;">central photographic review and validated disease assessment tools agreed</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 to compare SCENESSE® with adjunct NB-UVB vs NB-UVB monotherapy</li><li style="margin-top:0in; margin-bottom:0in;">CUV107 study (n=300) to commence in 2H 2026</li></ul> <p>MELBOURNE, Australia, April 24, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that the European Medicines Agency (EMA) has provided final scientific advice on the design of the planned pivotal Phase III CUV107 study and anticipated evaluation of evidence of CLINUVEL’s http://www.streetinsider.com/Globe+Newswire/CLINUVEL+receives+final+EMA+scientific+advice+for+pivotal+Phase+III+vitiligo+study/26361154.html Fri, 24 Apr 2026 01:47:00 -0400 A.31066700 CLVLY CUV O.00706064 O.22422661 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Press+Releases/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Globe+Newswire/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Globe+Newswire/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Globe+Newswire/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9 http://www.streetinsider.com/Globe+Newswire/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html <p>MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeting, the world’s largest gathering of dermatology professionals. Through the Company’s bespoke Pavilion of Photomedicine and conference sessions across five days, the development and commercialisation of CLINUVEL’s proprietary peptides in dermatology was presented to over 20,000 delegates.</p> <p>Building on momentum from the 2025 AAD meeting, AAD 2026 saw CLINUVEL’s ambition translate into deeper engagement with the medical community, with the Pavilion now an established hub for meaningful scientific exchange and candid dialogues. http://www.streetinsider.com/Globe+Newswire/CLINUVEL%3A+advancing+peptides+for+photomedicine+and+vitiligo+care+at+AAD+2026/26313726.html Wed, 15 Apr 2026 02:18:00 -0400 A.60012013 CLVLY CUV O.00706064 O.38236026 UR9 UR9